Results 341 to 350 of about 6,774,149 (386)
Some of the next articles are maybe not open access.

Sirtuin inhibitors

Expert Opinion on Therapeutic Patents, 2009
The sirtuin family of deacetylase enzymes comprises seven proteins (SIRT1-7) that are dependent on NAD(+) for their activity. Three proteins are located in the nucleus, three in the mitochondria and only one is predominantly cytoplasmic. Caloric restriction and oxidative stress generally up-regulate their expression. SIRT1, the orthologue of yeast Sir2,
Francisco J, Alcaín, José M, Villalba
openaire   +2 more sources

Renin Inhibitors

Pharmaceutical Research, 1987
Since the early 1980s, an intensive effort has been focused on the development of orally effective and long-acting inhibitors of renin. During this time, in vitro potency has increased greatly, with several transition-state inhibitor designs yielding inhibitors with subnanomolar IC50 values.
openaire   +3 more sources

PCSK9 inhibitors

Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire   +2 more sources

SGLT2 inhibitors

Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire   +2 more sources

Vasopeptidase inhibitors

The Lancet, 2001
Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE). They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II.
openaire   +2 more sources

Angiogenesis inhibitors

Current Oncology Reports, 2000
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
T R, Tennant   +2 more
openaire   +2 more sources

Thirty years of HDAC inhibitors: 2020 hindsight.

Journal of Medicinal Chemistry, 2020
It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical ...
Terence C. S. Ho, A. Chan, Arasu Ganesan
semanticscholar   +1 more source

HDAC Inhibitors

2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha   +3 more
openaire   +2 more sources

JAK2 inhibitors

Medicina Clínica (English Edition), 2016
Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms.
Juan Carlos, Hernández Boluda   +2 more
openaire   +2 more sources

Corrosion Inhibitors

2018
Advances in the field of corrosion inhibitors proceed in two main directions: (i) development of eco-friendly effective treatments and (ii) production of “smart” coatings. The first issue is connected to the more strict regulations regarding corrosion inhibitors application, due to environmental concerns.
openaire   +1 more source

Home - About - Disclaimer - Privacy